Recent polling shows oncologists changing inclination in treatment for mHSPC based on tolerability profiles.

The median BMI of the cohort was 26.7 kg/m 2 (range, 17.9–55.2). Patients were classified into 3 main weight categories based ...

RP1 and nivolumab combination achieved a 32.9% objective response rate and 15.0% complete response rate in advanced melanoma ...

The division of myelodysplastic syndromes (MDS) into low-risk and high-risk categories guides prognosis and treatment, with patients who have lower-risk disease typically receivin ...

Findings from a prospective phase 2 clinical trial show that isatuximab (Sarclisa), an anti-CD38 monoclonal antibody, is an effective and well-tolerated treatment for patients with relapsed and/or ...

Topline results from the phase 3 HERIZON-GEA-01 trial show that the HER2-targeted bispecific antibody zanidatamab-hrii ...

Visugromab combined with nivolumab showed a median duration of response exceeding two years in refractory NSCLC, UC, and HCC patients. GDF-15 is a therapeutic target and immune escape mechanism, ...

The FDA has granted an accelerated approval to sevabertinib (Hyrnuo) for the treatment of adult patients with previously ...

Future SCLC treatment may involve combining T-cell engagers with immune checkpoint inhibitors to enhance patient outcomes.

FDA fast track designation facilitates expedited development of DPTX3186, recognizing its potential to address serious unmet ...

The FDA approved enfortumab vedotin and pembrolizumab for MIBC, following a priority review of their sBLA for neoadjuvant and ...

A significant communication gap exists between NMIBC patients and providers, with only 18% having regular discussions about ...